A case report of advanced pancreatic neuroendocrine carcinoma with Ki67 80%, CPS 0, and pMMR achieving durable complete response for over 7 years after combination immunotherapy
This case demonstrates that multi-site, multi-dose, and multi-type radiotherapies can more effectively reveal the heterogeneous tumor antigens, and the combined therapy of immunotherapy and probiotics may achieve sustained immune responses.
Authors
- Yonghai Peng
- Yating Wu (ORCID: https://orcid.org/0000-0001-9280-7669)
- Hang Li (ORCID: https://orcid.org/0009-0007-9770-7633)
- Weiqiang Fan (ORCID: https://orcid.org/0000-0003-4328-5037)
- Hui Xu (ORCID: https://orcid.org/0000-0002-7596-8011)
Institutions
- Fuzhou Second Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1682148
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35